These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

61 related articles for article (PubMed ID: 8341928)

  • 41. Pathogenic role of interleukin-6 in the development of sepsis. Part II: Significance of anti-interleukin-6 and anti-soluble interleukin-6 receptor-alpha antibodies in a standardized murine contact burn model.
    Pallua N; Low JF; von Heimburg D
    Crit Care Med; 2003 May; 31(5):1495-501. PubMed ID: 12771624
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Horse cytokine/IgG fusion proteins--mammalian expression of biologically active cytokines and a system to verify antibody specificity to equine cytokines.
    Wagner B; Robeson J; McCracken M; Wattrang E; Antczak DF
    Vet Immunol Immunopathol; 2005 May; 105(1-2):1-14. PubMed ID: 15797470
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cytokine, chemokine, and co-stimulatory fusion proteins for the immunotherapy of solid tumors.
    Khawli LA; Hu P; Epstein AL
    Handb Exp Pharmacol; 2008; (181):291-328. PubMed ID: 18071951
    [TBL] [Abstract][Full Text] [Related]  

  • 44. New therapies for inflammatory bowel disease: an update on chimeric anti-TNF alpha antibodies and IL-10 therapy.
    van Hogezand RA; Verspaget HW
    Scand J Gastroenterol Suppl; 1997; 223():105-7. PubMed ID: 9200315
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Inhibition of allograft rejection and organ-specific autoimmune disease by anti-interleukin-2 receptor (IL-2R)-targeted immunotherapy. The action of anti-IL-2R monoclonal antibodies and synergistic effect of cyclosporin A.
    Diamantstein T; Mouzaki A; Osawa H; Volk HD; Hahn HJ; Kirkman RL; Strom TB; Tilney NL; Kupiec-Weglinski JW
    Dev Biol Stand; 1988; 69():177-84. PubMed ID: 3066671
    [No Abstract]   [Full Text] [Related]  

  • 46. The mode of action of cytokine inhibitors.
    Arend WP
    J Rheumatol Suppl; 2002 Sep; 65():16-21. PubMed ID: 12236617
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Preclinical and clinical development of immunocytokines.
    Sondel PM; Hank JA; Gan J; Neal Z; Albertini MR
    Curr Opin Investig Drugs; 2003 Jun; 4(6):696-700. PubMed ID: 12901228
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Interleukin 10 in disseminated lupus erythematosus].
    Emilie D
    J Soc Biol; 2002; 196(1):19-21. PubMed ID: 12134628
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [The role of biotherapy in multiple myeloma].
    Petrucci MT; Tafuri A; Mandelli F
    Recenti Prog Med; 2000 Oct; 91(10):488-93. PubMed ID: 11072735
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Up-to-date understanding of tuberculosis immunity].
    Mitsuyama M; Akagawa K; Kobayashi K; Sugawara I; Kawakami K; Yamamoto S; Okada Z
    Kekkaku; 2003 Jan; 78(1):51-5. PubMed ID: 12683337
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Anti-cytokine strategies.
    Dinarello CA
    Eur Cytokine Netw; 1992; 3(1):7-17. PubMed ID: 1581558
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Interleukin-2 receptor-directed therapies: antibody- or cytokine-based targeting molecules.
    Strom TB; Kelley VR; Murphy JR; Nichols J; Woodworth TG
    Adv Nephrol Necker Hosp; 1994; 23():347-56. PubMed ID: 8154364
    [No Abstract]   [Full Text] [Related]  

  • 53. [Anti-cytokines and anti-cytokine receptors].
    Dantal J; Giral M; Soulillou JP
    Rev Prat; 1993 Mar; 43(5):586-9. PubMed ID: 8341928
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Agents against cytokine synthesis or receptors.
    Yamagata T; Ichinose M
    Eur J Pharmacol; 2006 Mar; 533(1-3):289-301. PubMed ID: 16457805
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Targeting cytokines to tumors to induce active antitumor immune responses by recombinant fusion proteins.
    Xiang J
    Hum Antibodies; 1999; 9(1):23-36. PubMed ID: 10331183
    [TBL] [Abstract][Full Text] [Related]  

  • 56.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 57.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 58.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 59.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.